nogutsnoglory
Moderator
- Joined
- Sep 23, 2009
- Messages
- 8,908
"Among patients with Crohn’s disease who were treated with certolizumab pegol, those with low hematocrit had significantly shorter time to loss of remission compared with those who had normal hematocrit, according to a poster presentation here.
“This study for the first time shows that low hematocrit is an adverse prognostic factor for long-term outcomes with anti-TNF biologic therapy in Crohn’s disease,” William J. Sandborn, MD, chief of the division of gastroenterology and director of the UCSD IBD Center at University of California San Diego, told Healio Gastroenterology.
Using data from the 7-year PRECiSE 3 trial, Sandborn and colleagues evaluated the association between clinical and demographic characteristics and long-term remission in patients with moderate to severe Crohn’s disease treated with certolizumab pegol.
Compared with the 222 patients with low hematocrit (mean age, 37.4 years), disease duration, severity, location and behavior was similar among the 372 patients with normal hematocrit (mean age, 38.4 years).
Over the 7 year study period univariate time to discontinuation comparing low hemoglobin with normal hemoglobin was shown to be different (P=.0412), but hemoglobin was not included in the multivariate analysis. Patients with low hematocrit had shorter time to loss of remission compared with patients with normal hematocrit (P=.0481). Results were similar when “low” and “normal” hematocrit were defined by different values, and probability of maintenance of remission increased with incremental hematocrit increases. Multivariate analysis demonstrated that hematocrit level was an independent predictor of time to loss and maintenance of remission.
“This observation is analogous to the observation that low serum albumin is also an adverse prognostic factor,” Sandborn said. “In the case of albumin, low albumin is associated with increased clearance of anti-TNF biologics. We need to explore whether low hematocrit is also associated with increased clearance of anti-TNF biologics like certolizumab, which could potentially be a mechanistic explanation for this observation.”
http://www.healio.com/gastroenterol...ed-to-loss-maintenance-of-remission-in-crohns
“This study for the first time shows that low hematocrit is an adverse prognostic factor for long-term outcomes with anti-TNF biologic therapy in Crohn’s disease,” William J. Sandborn, MD, chief of the division of gastroenterology and director of the UCSD IBD Center at University of California San Diego, told Healio Gastroenterology.
Using data from the 7-year PRECiSE 3 trial, Sandborn and colleagues evaluated the association between clinical and demographic characteristics and long-term remission in patients with moderate to severe Crohn’s disease treated with certolizumab pegol.
Compared with the 222 patients with low hematocrit (mean age, 37.4 years), disease duration, severity, location and behavior was similar among the 372 patients with normal hematocrit (mean age, 38.4 years).
Over the 7 year study period univariate time to discontinuation comparing low hemoglobin with normal hemoglobin was shown to be different (P=.0412), but hemoglobin was not included in the multivariate analysis. Patients with low hematocrit had shorter time to loss of remission compared with patients with normal hematocrit (P=.0481). Results were similar when “low” and “normal” hematocrit were defined by different values, and probability of maintenance of remission increased with incremental hematocrit increases. Multivariate analysis demonstrated that hematocrit level was an independent predictor of time to loss and maintenance of remission.
“This observation is analogous to the observation that low serum albumin is also an adverse prognostic factor,” Sandborn said. “In the case of albumin, low albumin is associated with increased clearance of anti-TNF biologics. We need to explore whether low hematocrit is also associated with increased clearance of anti-TNF biologics like certolizumab, which could potentially be a mechanistic explanation for this observation.”
http://www.healio.com/gastroenterol...ed-to-loss-maintenance-of-remission-in-crohns
